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The perspective of disease development can often be attributed for deregulation of gene expression. 
Hepatocellular carcinoma (HCC) has a high frequency of occurrence amongst all malignancies worldwide. 
Chronic Hepatitis B Virus (HBV) infection is one of the root causes of inception of this disease in humans. 
Information about microRNA mediated regulation of viral infections is just emerging. MicroRNAs (miRNAs) 
are about 19- 23 base pair long functional transcripts that govern gene expression by cleavage or translational 
repression of target mRNA. Oncogenic (or tumor suppressive) roles of miRNA in many aspects of cancer biology 
and wide spread differential expression of miRNAs in different stages of HBV associated Hepatocellular 
Carcinoma (HCC) compared with normal tissues are well documented. During HBV infection, perturbations of 
miRNA expression particularly cell cycle regulating miRNAs might have significant correlation with HCC 
development. Hepatitis B virus X protein (HBx) acts as a multifunctional protein that balances cell proliferation 
and programmed cell death by its anti-apoptotic and pro-apoptotic function. HBx interacts with various nuclear 
transcription factors and brings about transcriptional activation. It also modulates several cytoplasmic signaling 
pathways contributing to cell proliferation and survival. HBx is often referred as oncoprotein for its significant 
role during development of HCC. HBx-miRNA interaction in HBV related HCC has been at the core of much 
scientific interest over last few years. HBx is found to modulate several miRNAs that are associated with HBV 
related HCC. This review concentrates on the interaction of HBx protein with some of the miRNAs that are 
essentially associated with cell proliferation and found modulated in HCC. HBx-miRNA interactions provide a 
fresh understanding of the potential modus of viral protein action utilizing miRNA to control host functioning. 
Finally, the HBx-miRNA interaction could be utilized as a curative approach for management of HBV associated 
HCC. 
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Hepatocellular carcinoma (HCC) is a widely prevalent and 
potentially fatal malignancy. HCC accounts for 5.6% of all 
cancers [1]. The occurrence of HCC is the fifth highest 
amongst all cancers and is the third highest cause of deaths 
from cancer [2]. Death due to HCC is quite common in Asia 
and current estimate is that there are 450,000 people dying 
from this disease every year. The following conditions 
increase the likelihood of developing this disease: hepatitis B 
virus (HBV) infection, hepatitis C virus (HCV) infection, 
intake of food adulterated with aflatoxin B1, excessive 
consumption of alcohol and nonalcoholic fatty liver disease 
[3]. Chronic Hepatitis B Virus (HBV) infection can lead to 
severe pathological conditions, the most severe ones being 
liver cirrhosis (LC) and HCC. Hepatitis B virus X protein 
(HBx) which is denoted by the X open reading frame (ORF) 
of the HBV genome is known to be involved in the viral 
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infection, pathogenesis and replication though its precise 
function in viral replication is not yet established. HBV X 
protein has been in the spotlight in recent years because 
several reports documented its crucial role in the inception of 
HCC. 
MicroRNAs (miRNAs) have been identified relatively 
recently and are a group of functional transcripts in 
eukaryotic cells [4]. miRNAs are 21 to 23-nucleotide long 
highly conserved RNA molecules that govern the stability or 
translational efficiency of target mRNAs [5]. Role of miRNA 
is being revealed in almost every field of research on 
malignancy, such as proliferation, tumorigenesis, 
invasion/metastasis, angiogenesis and apoptosis [6, 7]. 
Interaction between multiple intricate signal transduction 
pathways are regulated by these diminutive RNAs. Various 
studies have revealed significant differentiation in the 
expression of miRNA genes in malignant tissues in 
comparison to non-malignant tissues [8]. 
Fresh evidence is coming to light regarding the 
interrelationship between miRNAs and HBV X protein. 
Involvement of HBx in the modulation of several miRNAs 
that are found to associated with various types diseases 
especially cancer is well recognized. Several studies reported 
that miRNA-21, miRNA-222 and miRNA-145 are modulated 
Figure 1. An overview of host factors modulated by HBx. A. Linear depiction of the HBV genome with regulatory elements such as 
DR1, DR2, Enh1, Enh2. Numbers indicate nucleotide position, using EcoRI-based numbering system. B. The overlapping open reading 
frame of Four HBV genes (C, S, Pol, and X) showed as coloured solid boxes. C. HBx protein. Numbers indicate amino acid position. D. 
Host factors modified by HBx protein. 
 
RNA & DISEASE 2015; 2: e818. doi: 10.14800/rd.818; © 2015 by Manikankana Bandopadhyay, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 3 of 8 
 
in hepatocellular carcinoma. HBx and miRNAs both are 
known to be critically involved in cell proliferation and 
neoplastic transformation. Though quite a few reports have 
revealed many aspects of HBx and miRNA interaction, 
present review focusses on involvement of HBx protein of 
HBV modulating the expression of miRNA-21, miRNA-222 
and miRNA-145 in hepatic cancer cells thereby revealing 
miRNA mediated complex host viral interaction leading to 
cell proliferation that eventually culminate towards hepatic 
cancer. 
Hepatitis B virus X protein and hepatocellular carcinoma 
HBV genome contains four overlapping open reading 
frames among which the smallest X ORF denotes for 
hepatitis B virus X protein (HBx). HBx is 154 amino acid 
long 17 KDa protein that bears two functional domains with 
opposite functions - the N-terminal domain with negative 
regulatory / anti-apoptotic function and the C-terminal 
domain with pro-apoptotic / transactivation function (Figure 
1). The HBx protein is found mainly in the cytoplasm and 
though in a small amount, the nucleus of hepatocytes. HBx is 
often referred as proto oncogenic factor as it modulates host 
gene expression by stimulating a number of cytoplasmic 
signaling pathways like NF-κB, Src, Ras, AP-1, AP-2, 
PI3K/Akt, Jak/STAT, Smad and Wnt [9, 10]. Multifunctional 
HBx protein acts as transcriptional transactivator by 
interacting with both nuclear transcription factors (e.g., 
CREB, ATF-2, Oct-1, TBP) and basal transcription factors 
[11] that causes increased cell proliferation and survival [12]. 
Other cellular processes that are modulated by HBx are 
reduction of DNA repair, activation of mitogen activated 
protein kinase (MAPK) pathways. HBx acts as pro apoptotic 
and anti apoptotic factor through induction of apoptosis by 
altering the TNFα and NF-κB signaling pathways [13, 14, 15] 
and inhibition of p53-mediated apoptosis by direct interface 
with p53 respectively [16]. Informations are present that HBx 
protein increases the expression of TERT and telomerase 
activity, thereby increasing the lifespan of hepatocytes thus 
converting to malignancies [17]. Several in vivo experiments 
were performed to examine the contribution of HBx in the 
development and progression of HCC. The first model of 
transgenic mouse contained HBx expression vector that 
included the HBV X coding sequence, the X gene promoter 
along with HBV enhancer I region and the polyadenylation 
signal. It was evident that tumor development in the liver 
tissue was directly associated with HBx expression [18]. Yu et 
al using an identical expression construct, later re-established 
this finding in another descent of transgenic mice [19]. A 
recent elaborate study by Ye H et al used hepatocyte-specific 
Kras (G12D) transgenic mouse model and found functional 
interaction between HBx and Kras (G12D) during the 
initiation and progression of HCC. They observed that the 
Akt, MAPK, p53 and TGF-β signaling pathways are more 
pronouncedly modulated in Kras (G12D) + HBx double 
transgenic mice than in vitro study of Kras (G12D)-driven 
HCCs [20]. Taken together, HBx may cause hepatocytes to 
become more susceptible to diverse carcinogenic signals. 
Such signals interact with the immune response of the host 
and along with the interplay between cellular proteins and 
HBx, may significantly increase the occurrence of hepatocyte 
transformation [21, 22, 23, 24] which advances towards HCC.  
miRNA in hepatocellular carcinoma 
The viewpoint of gene regulation has mainly emphasized 
on protein coding genes following the consecutive direction 
of DNA → RNA → protein. Recent advancement in 
technology, for example, parallel sequencing and high 
resolution microarray has enabled us to know that about 90% 
of the human genome transcribe into non-coding RNAs 
(ncRNAs) and less than 2% of the genome actually have the 
protein coding potential [25]. Depending upon size, ncRNAs 
are grouped into two categories- small ncRNAs (‹200bp) and 
long ncRNAs (lncRNAs). Among the small ncRNAs, 
miRNAs are the crucial regulator of gene expression and 
various cellular processes like proliferation, development, 
differentiation, apoptosis and tumorigenesis.  Multiple 
studies indicate that miRNA expression is significantly 
affected in cancerous tissues as a result of numerous genomic 
and epigenetic modifications. The types of expression of 
miRNA are related to type of malignancy, its degree of 
advancement and other clinical factors. Analyses of miRNA 
expression have revealed that miRNAs can have both 
oncogenic and tumor-suppressive properties, depending upon 
target genes. Evidences have accumulated regarding 
modulated expression of miRNA in HCC. For example, 
miR-21[26, 27, 28, 29], let-7a [28] and miR-224 [29] are found 
elevated in HCC. Expression of miR-145 is found to be 
altered in HuH 7 cell line, human HCCs [30] and also in 
carcinomas from other tissues. Higher expression of miR-221 
and miR-222 directly causes down regulation of the 
well-known tumor suppressor and cell cycle regulator gene 
p27 (Kip1) [31]. miR-1269 was found overexpressed in HCC 
cells and tissues. Ectopic expression of miR-1269 promoted 
proliferation, tumorigenicity and cell cycle progression of 
HCC cells, whereas inhibition of miR-1269 reduced the same 
in hepatoma cells [32]. miR-362-5p was found significantly 
elevated in HCCs and inhibition of miR-362-5p caused 
remarkable decrease in cell proliferation, migration, invasion 
and clonogenicity in vitro as also tumor growth and 
metastasis in vivo. This finding reveal oncogenic role of 
miR-362-5p that acts through CYLD (target mRNA) to 
activate the NF-κB signaling which contributes to 
progression of HCC [33]. miR-141 serves as a tumor 
suppressor in hepatocarcinoma cells through the impediment 
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of Hepatocyte Nuclear Factor-3β (HNF-3β) translation. 
HNF-3β is crucially involved during hepatocyte 
differentiation and controls expressions of liver-specific 
genes during HCC development [34]. All of these evidences 
reveal that multiple genomic and epigenetic modifications 
are responsible for the differential expression of microRNAs 
between malignant versus normal tissues. 
HBx and miRNA 
HBx is found to be associated with the modulation of 
several miRNAs that are found to be connected with 
molecular pathogenesis of various types diseases particularly 
cancer. There are a number of recent publications reporting 
on the interplay between miRNA and HBx protein. HBx is 
reported to have produced extensive modification of 
miRNAs in HepG2 cells. The first report of HBx induced 
modulation of miRNAs in HepG2 cells was revealed by 
Wang et al [35]. A number of studies emphasized about 
interaction between HBx protein and miR-15a/16. Along 
with a number of miRNAs, reduced expression of the 
miR-16 family was noted in HBx expressing hepatoma cells 
(HepG2, Huh7 and SK-HEP-1) by microarray technique and 
quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR). Moreover, down regulation of miR-15a/16 in 
HBx expressing HepG2 cells was found host c-Myc gene 
mediated [36]. An Interesting study by Wang et al [37] revealed 
that HBx transcript mediate the repression of 
miR-15a/miR-16-1 through the microRNA targeting 
sequence in the HBV RNA. Recently, Li et al [38] 
demonstrated that HBx causes up regulation of miR-146a 
expression through NF-κB mediated activation of miR-146a 
promoter which in turn reduced the expression of its direct 
target, complement factor H (CFH). The reduced CFH 
expression is found to be associated with liver inflammation. 
HBx induced down regulation of miR-101 elevated 
expression of DNA methyl transferase 3A which is 
responsible for aberrant DNA methylation of many tumor 
suppressor genes [39]. HBx, either viral transcript or protein is 
able to control the expression of specific microRNAs, thus 
expanding the biological and pathological properties of the 
oncogenic HBX gene in the HBV biology. 
Hepatocellular tumor development is a multistep process 
and involves several structural, genetic and epigenetic 
alterations. Three main basic aspect of neoplastic growth are 
increased cell proliferation, decreased apoptosis and 
increased angiogenesis. We emphasized our discussion on 
HBx mediated modulation of few miRNAs that are involved 
in cell proliferation process through regulation of their target 
genes.  
HBX down regulated miRNA -21 in malignant hepatocytes 
miR-21 is often referred as  oncomiRNA as its 
expression is frequently found increased in various types of 
cancers like hepatocellular carcinoma, cholangiocarcinoma 
[40], glioblastoma [41], pancreatic cancer [42], breast cancer [43], 
stomach cancer [42], thyroid cancer [44], colon cancer [45] and 
prostate cancer [42]. miR-21 stimulated cell proliferation, 
migration and invasion In HCC tissues and multiple HCC 
cell lines by suppressing the expression of widely 
acknowledged tumor-suppressor genes such as Phosphatase 
and Tensin homologue (PTEN) and Programmed Cell Death 
Protein-4 (PDCD4) [46], [47]. New reports are emerging about 
HBx miR-21 interaction and involvement of HBx protein in 
the regulation of hepatoma cell proliferation. A recent study 
by Damania et al [48] showed that HBx can induce cell 
proliferation through modulation of miR-21 expression, 
which consecutively prevents PDCD4 and PTEN expression 
and stimulates Akt. Li et al demonstrated that miR-21 
expression is dependent upon HBx protein of HBV and over 
expression promotes development of HCC in hepatocytes 
through HBx-induced IL-6 pathway following STAT3 
activation [49]. 
A study from our lab revealed that expression of miR-21 
was found reduced in HBx transfected HepG2 cells [50]. 
HepG2 cells when transfected with full length HBV genome, 
exhibited the similar result.. HepG2.2.15 cell line is a 
modified HepG2 cell that contains a plasmid carrying four 
5/-3/ tandem copies of full length HBV genome.  In 
HepG2.2.15 cells we observed a down regulation of miR-21 
expression too. PTEN is one of the reported, valid targets of 
miR-21. PTEN is a phosphatase that dephosphorylate PIP3 
producing the bisphosphate product PIP2. This 
dephosphorylation causes inhibition of the AKT signaling. 
Accordingly PTEN expression was found elevated in HBx 
transfected HepG2 cells and HBV replicating HepG2.2.15 
cells. When 3 cellular system i.e. HBx transfected HepG2, 
HBV genome transfected HepG2 and HepG2.2.15 cells were 
treated with HBx-mRNA specific siRNA, we could found 
that miR-21 expression was restored at different time points 
compared to the control cell line. In addition, significant 
down regulation of miR-21 was observed in advanced liver 
disease patients or its subsets LC and HCC groups. We 
would like to mention that our study was performed using 
HBx of HBV genotype D. The results of our study are, 
therefore, reflective of the responses characteristic of the 
HBV genotype D. 
miRNA-222 was down regulated by HBx protein in 
transiently transected HepG2 cells and in constitutively 
HBV producing HepG2.2.15 cells 
miR-221 and miR-222 are found on the X-chromosome 
and positioned in tandem. Various studies have demonstrated 
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that miR-222 expressions are often modulated in HCC. 
Guanine nucleotide binding protein, alpha inhibiting activity 
polypeptide 3 (GNAI3) prevents migration and invasion of 
HCC cell. By software predictions and experimental 
screening, Zhang et al [51] very recently found that miR-222 
could directly bind to GNAI3 mRNA and decrease GNAI3 
protein expression in HCC cells. Their study collectively 
demonstrated that GNAI3 deters cell migration and invasion 
in HCC and is post-transcriptionally controlled by miR-222. 
The p27 (Kip1) gene is one of the targets of miR-222. p27 
belongs to the Cip/Kip family of cyclin dependent kinase 
(CDK) inhibitors. It is a cell cycle regulatory protein that 
binds to CDK2 and cyclin E complexes and inhibit cell cycle 
progression at G1 [52]. Sage et al [53] have proved that miR - 
221& miR - 222 can suppress p27 (Kip1) expression and in 
that manner are responsible for cancer development. 
miR-221, miR-222 can be attributed as a novel member of 
oncogene family as overexpression of these miRNAs can 
cause down regulation of the p27(Kip1) mRNA which is 
critically involved in cell cycle regulation and tumor 
suppression. Our study with miR-222 revealed that miR-222 
is found down regulated in HBx and HBV transfected 
HepG2 cells and also in HepG2.2.15 cell. Consequently, 
increased p27 mRNA and protein expression was observed in 
these aforementioned cell lines. Interestingly, when HBx 
transfected HepG2 cells and HBV transfected HepG2 cells 
were treated with HBx specific siRNA, miR-222 expression 
was reestablished in those transfected HepG2 cells than their 
control cells. Likewise, miR-222 expression was restored in 
HBx silenced HepG2.2.15 cells. Our results demonstrated 
that HBx is responsible for the suppression of miR-222 
expression, in that way increasing the expression of p27. 
Other group of researchers with their in vitro study and 
experiments on mouse primary hepatocytes previously 
proved that HBx can increase the expression of p27 which in 
turn can cause cell cycle arrest in G1-S phase [54, 55]. 
Moreover, our study on HBV infected advanced liver disease 
patients with different clinical outcomes such as LC and 
HCC subsets revealed that miR-222 expression was reduced 
compared to healthy individuals. 
miRNA-145 is differentially modulated by HBx protein in 
malignant hepatocytes 
miR-145 is widely acknowledged as a tumor suppressing 
miRNA, as there are ample evidence of under expression in 
many types of tumors [56]. Sachdeva et al performed 
elaborate work on miR-145. They have shown that miR-145 
is a direct target of p53. p53 binds to a p53 response element 
(p53RE) present in the miR-145 promoter region and induces 
the transcription of miR-145. Notably, miR-145 has a 
negative relation with oncogene c-Myc as elevated level of 
miR-145 reduces c-Myc expression, while inactivation of 
endogenous miR-145 increases c-Myc expression. The 
inhibition of tumor cell growth, both in vitro and in vivo can 
be explained, at least partly, by miR-145 mediated post 
transcriptional regulation of c-Myc gene by p53. [57]. 
However, limited information is available regarding down 
regulation of miR-145 in tumors. Sachdeva et al have 
identified the putative CCAAT/enhancer binding protein beta 
(C/EBP-β) binding site in the miR-145 promoter region and 
C/EBP-β acts as a negative regulator for miR-145 expression 
by direct interaction with it. In the presence of wild-type p53 
allele, C/EBP-β thwarts the ability of p53 to induce miR-145. 
In addition, C/EBP-β can suppress miR-145 expression in the 
mutant p53 background, signifying the p53 independent 
regulation of miR-145. They have further showed that, the 
antioxidant resveratrol possess the ability to suppress pAkt 
and phosphorylation of C/EBP-β and simultaneously, it can 
induce miR-145. Taken together, their experimental findings 
demonstrate a miR-145 regulatory system involving the Akt 
and C/EBP-β, which may explain the reduced miR-145 
expression in cancer cells [58].  
We found reduced expression of miR-145 when HepG2 
cells were transfected with HBx plasmid and full length 
HBV genome. HBx protein is known to activate Ras-GTP 
complex and can establish Ras Raf MAP kinase signal 
cascade [59]. Previous study reported HBx can stimulate 
Ras-activating proteins of the Src family of tyrosine kinases, 
which passes signal to Ras [60]. Our result is in synchronization 
with aforesaid study as reduced expression of miR-145 by 
HBx caused increased expression of MAP3K (Raf 1) which is 
known to be effectively involved in cellular growth and 
proliferation by modulating downstream signaling molecules. 
Therefore, it appears from our study that HBx induces cell 
growth and proliferation by suppressing the expression of 
miR-145.  
However, miR-145 was found over expressed in 
HepG2.2.15 cell line than control HepG2 cells. Its target 
MAP3K (Raf 1) protein expression was found decreased in 
HepG2.2.15 cells when compared with control HepG2 cell 
line. An early study by Jiang et al [61] showed that the 
expression of miR-145 is increased by more than 5 fold in 
HepG2.2.15 than in HepG2 cells. HepG2.2.15 cells carry 
HBV DNA as chromosomally integrated sequences and 
episomally as relaxed circular DNA as well as covalently 
closed form of HBV genome (CCC) [62]. Evidences confirm 
that chronic HBV induced HCC involves both integrated 
HBV DNA as well as CCC episomal HBV genome. 
Integration into the host chromosome exerts cis effects 
resulting in interruption of cellular genes that are crucial for 
cell growth and proliferation. Alternatively, trans-activating 
factors like HBx from episomal HBV DNA are responsible 
for modulation of various cell signaling pathways in the 
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cytoplasm leading to hepatocarcinogenesis [63]. It can be 
presumed that the HBV uses both the mechanisms in HBV 
related HCC leading to a difference in expression of miR-145 
between transiently transfected HepG2 cells and HBV 
genome integrated HepG2.2.15 cell line. Still, future 
mechanistic study is required to explain the exact reason 
behind the modulation of miR-145 expression. 
Conclusion and future direction 
Overall, we summarized the involvement and mechanism 
of HBx mediated regulation of miRNAs that are associated 
with HBV related hepatocarcinogenesis. The process of 
cancer development is dependent on a number of factors, 
which include direct and indirect mechanisms which 
sometimes operate in a coordinated manner. Available 
experimental evidences indicate that there a number of 
molecules and pathways that influence the inception and 
advancement of HCC, however, the specific modus through 
which HBx causes carcinogenesis continues to be 
inconclusive. Along with cell-transforming potential, 
interaction with numerous transcription factors and diverse 
cell signalling pathways, modulating apoptosis and the 
immune system, interaction of HBx protein with regulatory 
RNAs like miRNAs is also a crucial event during 
development of hepatic cancer.  
HBx-miRNA interactions provide new understanding of 
the likely action of viral protein on microRNA and the 
resultant impact on functioning of the host cell. Disease 
severity and development of hepatocarcinogenesis is often 
associated with viral genotype of HBV. The interdependence 
between cellular miRNA and HBx protein having its genesis 
in remaining genotypes of HBV remains a subject of further 
investigation. Furthermore, future studies need to be 
conducted to understand how the HBx-miRNA interactions 
can be used as a curative strategy to restrict the inception and 
growth of HBV related HCC and investigation of these 
interactions in vivo should be the focus of such studies. 
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